2ND ANNUAL
ADVANCES IN
IMMUNO-ONCOLOGY
USA CONGRESS

08 - 09 October 2019 | DoubleTree by Hilton Hotel San Diego – Mission Valley, USA

200+
LEADING ACADEMIC, PHARMA
AND BIOTECH DELEGATES

40+
PRESENTATIONS, CASE
STUDIES AND DISCUSSIONS

6+
HOURS OF NETWORKING
SESSIONS

Conference Brochure

KEY SPEAKERS INCLUDE

Catherine Sabatos-Peyton
Novartis

Zhongwu Lai
AstraZeneca

Ruth Seelige
Pfizer

Naveen Dakappagari
Navigate BioPharma

Chris Twitty
OncoSec

Ross Stewart
Pfizer

Book Online: www.oxfordglobal.co.uk/immunooncologyusa-congress
Join the Conversation: #ImmunoUS19
Oxford Global is proud to present for the second year our Advances in Immuno-Oncology USA Congress. Following on from the success of the inaugural event, the congress has been expanded for 2019 and now features over 40 presentations evaluating the latest strategies and technologies impacting the global immuno-oncology marketplace. It unites over 200 attendees from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutes to provide a focused forum for thought-provoking discussion.

The comprehensive programme allows you to gain a forward-looking perspective on current opportunities across four phase-based streams, from therapeutic strategies and modelling through to the latest clinical data. Hear case studies across a variety of key therapeutic strategies: cell therapies, checkpoint inhibitors and oncolytic viruses. A special focus on biomarker development through the co-located 4th Annual Biomarkers & Precision Medicine USA Congress provides updates on patient selection in clinical trials, new biomarker technologies, personalised therapies and genomic markers.

Don’t Miss Our Complimentary Webinar

Thursday 29th August 2019, 5:00pm GMT / 9:00am PST

How CD8 Imaging Is Useful To Pharma Regarding Drug Research And Clinical Decision Making

hosted by Ivan Plavec, Chief Business Officer, ImaginAb

Click here to register your interest or download past webinars from our Resources page
200+ VPs, Directors & Senior Managers from leading life sciences companies and research institutions in the following fields:

- Immuno-Oncology
- Target Discovery
- Oncology Biomarkers
- Clinical Trial Management
- Antibody Development
- Agonist Antibodies
- Clinical Oncology
- Cancer Vaccines
- Immunotherapy
- Combination Therapy
- Oncology Cell Therapy
- Precision Medicine

These companies and many more

For the full attendee list please contact marketing@oxfordglobal.co.uk

Formal and informal meeting opportunities offer delegates the chance to meet with leading service providers and discuss key solutions including:

- Clinical Development
- Strategic Partnerships
- Cell-based Assays
- Antibody Engineering
- Custom Antibodies
- Clinical Management
- Diagnostics Development
- Cell Engineering
- T-Cell Engineering
- Mouse Models
- In Vitro Screening
- Immunohistology

For sponsorship enquiries, please contact sponsorship@oxfordglobal.co.uk
The 2nd Annual Advances In Immuno-Oncology USA Congress features 4 interactive streams which include over 40 presentations, case studies and panel discussions focused on the key issues in the industry today:

**DAY ONE: 08 OCTOBER**

**DISCOVERY OF IMMUNO-ONCOLOGY THERAPIES**
- Key therapeutic strategies in Immuno-Oncology
- Checkpoint inhibitors
- Oncolytic viruses
- CAR-T Cell Therapies
- Adoptive cell transfer
  - Immune-Stimulating Antibody Conjugates
- Determining the right model in immuno-oncology therapies
- Immuno-Oncology drug discovery case studies

**TRANSLATIONAL IMMUNO-ONCOLOGY**
- Translational science in immuno-oncology
- Biomarker strategies in the era of PD-1 checkpoint combination therapies
- New biomarker technologies in translation and the prediction of response
- Technologies for biomarker development: Cytob and spectrometry
- Target Validation Techniques

**DAY TWO: 09 OCTOBER**

**PRECLINICAL DEVELOPMENT – SCREENING, ASSAYS AND MODELLING IN IMMUNO-ONCOLOGY**
- Preclinical models including humanised mouse models
- Mouse models to guide decisions in the clinic
- Novel target identification techniques
- Approaches to preclinical combination therapy design
- Reducing toxicity and cytokine in immuno-oncology therapeutics
- Alternative screening strategies
- Screening techniques in vivo and in vitro models

**IMMUNO-ONCOLOGY CLINICAL RESEARCH & TRIALS**
- Approaches to clinical trial design and development
- Key safety challenges in cancer immunotherapy trials
- Predicting toxicity of immunotherapies
- Platform strategies in clinical development
- Clinical data & case studies:
  - Therapeutic cancer vaccines
  - CAR T Cell therapies
2nd Annual Advances in Immuno-Oncology USA Congress

DAY ONE: 08 OCTOBER

07:30 - 08:20
Registration: South Foyer

08:20
Conference Room: Brickstones
Oxford Global Welcome Address

08:25
Chairperson’s Opening Address: MARK MOONEY, Vice President of Customer, Tag.bio

08:30 - 09:00
Keynote Address: Going Beyond “Traditional” CAR-T Therapy
• Advantages and Disadvantages of Autologous CAR-T Therapy: Time to therapy, Complications and Cost
• Advantages and Disadvantages of Allogeneic Engineered T Cell Therapy: Time to therapy, Complications and Cost
• Alternatives to Engineered T Cell Therapy: mAb, mAb ADC, bisAB and Oncolytic Viruses

JEROME ZELDIS, Chief Medical Officer & President of Clinical Research, Medical Affairs & Regulatory, Sorrento Therapeutics

09:00 - 09:30
Stream Keynote Address: Redirecting The Specificity Of T Cells For Hematologic Malignancies And Solid Tumours
• Role of DNA plasmids from Sleeping Beauty (SB) system to reduce the cost and complexity of manufacturing T cells express chimeric antigen receptor (CAR) and T-cell receptor (TCR)
• Personalized T-cell therapy using DNA plasmids from SB system to target neoantigens from solid tumors
• Expression of cytokines to improve the therapeutic potential and improve safety of genetically modified T cells

LAURENCE COOPER, Chief Executive Officer, Ziopharm

09:30 - 10:00
Question To Answer Analysis: On The Fly Gene Signatures Across The TCGA Clinical Data Resource
• Rapid and iterative analysis on large oncology datasets
• Transferrable analysis protocol apps
• Data sites for collaborative analysis

MARK MOONEY, Vice President of Customer, Tag.bio

10:00 - 11:20
Exhibition Area: Great Room
Morning Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions

08:20
Stream Chair: MARK MOONEY, Vice President of Customer, Tag.bio

08:25
Keynote Address: Going Beyond “Traditional” CAR-T Therapy

08:30 - 09:00
Stream Keynote Address: Redirecting The Specificity Of T Cells For Hematologic Malignancies And Solid Tumours

09:00 - 09:30
Question To Answer Analysis: On The Fly Gene Signatures Across The TCGA Clinical Data Resource

09:30 - 10:00
Question To Answer Analysis: On The Fly Gene Signatures Across The TCGA Clinical Data Resource

09:30 - 10:00
Question To Answer Analysis: On The Fly Gene Signatures Across The TCGA Clinical Data Resource

10:00 - 11:20
Exhibition Area: Great Room
Morning Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions

08:20
Stream Chair: MARK MOONEY, Vice President of Customer, Tag.bio

08:25
Keynote Address: Going Beyond “Traditional” CAR-T Therapy

08:30 - 09:00
Stream Keynote Address: Redirecting The Specificity Of T Cells For Hematologic Malignancies And Solid Tumours

09:00 - 09:30
Question To Answer Analysis: On The Fly Gene Signatures Across The TCGA Clinical Data Resource

09:30 - 10:00
Question To Answer Analysis: On The Fly Gene Signatures Across The TCGA Clinical Data Resource

10:00 - 11:20
Exhibition Area: Great Room
Morning Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions

10:00 - 11:20
Exhibition Area: Great Room
Morning Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions

10:00 - 11:20
Exhibition Area: Great Room
Morning Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions

10:00 - 11:20
Exhibition Area: Great Room
Morning Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions
2nd Annual Advances In Immuno-Oncology USA Congress
DAY ONE: 08 OCTOBER

STREAM 1
DISCOVERY OF IMMUNO-ONCOLOGY THERAPIES
Conference Room: Brickstones

Tumor-Targeted Immune-Stimulating Antibody Conjugates
- Antigen presenting cells (APCs) process tumor antigens and facilitate recruitment of tumor-specific T cells to generate a robust anti-tumor immune response
- The highly immunosuppressive tumor microenvironment (TME) often renders APCs unable to effectively process and present tumor antigens
- To overcome an immunosuppressive TME and rescue the function of tumor-infiltrating APCs, we developed an immune-stimulating antibody conjugate (ISAC)
- ISACs are tumor-targeting monoclonal antibodies that deliver a powerful innate immune-stimulating agent, such as a TLR agonist, directly to the tumor and reinvigorate APCs to produce a powerful anti-tumor innate and adaptive immune response

DAVID DORNAN, Senior Vice President and Head of Research, Bolt Biotherapeutics, Inc.

STREAM 2
TRANSLATIONAL IMMUNO-ONCOLOGY
Conference Room: Shuters East I

Efficacy And Safety Biomarkers Of Cancer Immunotherapies Identified By Novel Digital Pathology And Flow Cytometry Approaches
- Clinical case studies illustrating the use of novel quantitative digital pathology algorithms and high complexity flow cytometry approaches for identification of efficacy/predictive biomarkers of PD-1 blockers, anti-CTLA4 + IFNalpha and first approved CAR-T therapy will be described in the setting of Melanoma, Head and Neck Cancer and Diffuse Large B-Cell Lymphoma
- Correlation between tissue and blood biomarkers will be illustrated within a subset of clinical studies

NAVEEN DAKAPPAGARI, Head, Protein Biomarker Solutions, Navigate BioPharma

STREAM 1
DISCOVERY OF IMMUNO-ONCOLOGY THERAPIES
Conference Room: Brickstones

Exhausted But Not Dead: In Vitro T Cell Exhaustion To Assess The Effects Of Candidate Therapeutics
- How is T cell exhaustion defined?
- Generating exhausted T cells and confirming exhaustion
- Other effects on exhaustion

JULIETTE LAMY, Senior Scientist, ImmunXperts

STREAM 2
TRANSLATIONAL IMMUNO-ONCOLOGY
Conference Room: Brickstones

Accelerating Therapeutic Antibody Discovery With Fully Human Antibody (RenMab) Mice And Humanized Animal Models
- Biocytogen has recently developed RenMab Mouse, a fully human antibody mouse with its entire variable regions replaced by human Ig heavy chain and light chain
- Combined with Biocytogen's existing inventory of single, double or triple humanized immune checkpoints mouse models and cytokine/cytokine receptors mouse models such as B-hCD40, B-h4-1BB, B-hOX40, B-hCD3e, B-hIL4/I4Ra, B-hIL17A, B-hIL33, RenMab provides a streamlined therapeutic antibody discovery platform for human antibody generation, characterization, and rapid in vivo antibody efficacy screening
- Hundreds of humanized models covering various therapeutic areas are under development
- Together with dedicated preclinical teams with strong in vivo, ex vivo and in vitro capabilities, Biocytogen is poised to serve the biomedical community as an one-stop solution provider from target validation to IND application

CHAOSHE GUO, Vice President, Global Head of Business Development, Biocytogen

STREAM 1
DISCOVERY OF IMMUNO-ONCOLOGY THERAPIES
Conference Room: Brickstones

Panel Discussion: Novel Therapeutic Targets In IO - Opportunities And Challenges
Panel Moderator: LOUI MADAKAMUTIL, Senior Vice President, Head of Preclinical Development, Nektar Therapeutics
Panelists:
- CATHERINE SABATOS-PEYTON, Director, Novartis
- MAURIZIO ZANETTI, Director of Tumour Immuno-Oncology, University of California San Diego
- SEAN CARROLL, Associate Director, Atreca
- DAVID DORNAN, Senior Vice President and Head of Research, Bolt Biotherapeutics, Inc.

STREAM 2
TRANSLATIONAL IMMUNO-ONCOLOGY
Conference Room: Shuters East I

Harnessing The Power Of Intratumoral IL-12 To Achieve Systemic Immunity In A Post Anti-PD-1 Setting
- Background on OncoSec's therapeutic platform and rationale for its combination with anti-PD-1 therapies in a post-anti-PD-1 setting
- Biomarker data from OncoSec's IL-12 trials +/- pembrolizumab combination in patients with metastatic melanoma suggest that intratumoral IL-12 can directly license the TME via sustained IL-12/IFN-g-driven immunity, allowing for a reversion of anti-PD-1 resistance
- Leveraging immunological data from the biomarker program to evolve OncoSec's therapeutic platform (plasmid therapeutic and applicator to reach interior/visceral lesions

CHRIS TWITTY, Chief Scientific Officer, OncoSec

STREAM 1
DISCOVERY OF IMMUNO-ONCOLOGY THERAPIES
Conference Room: Brickstones

Advancing Precison Oncology Biomarker Discovery With A Multidimensional Immunogenomics Platform
- The search continues to ascertain biomarkers that will improve the selection of patients who will best respond to immunotherapies and help tailor these promising treatments
- The complexity of both the tumor and tumor microenvironment suggests a more comprehensive approach is needed for robust and accurate characterization of the cancer ecosystem
- The Immunoid Next platform consolidates multiple biomarker assays into one with the ability to detect neoantigens, characterize the immune repertoire and identify novel biomarker signatures from a single sample
- We’ll discuss how to overcome barriers in translational research with this innovative assay design and optimized analytics for maximizing data generation for precision oncology

KEDAR HASTAK, Field Application Scientist, Personalis, Inc.

Exhibition Area: Great Room
Lunch, One To One Meetings x2, Poster Presentation Sessions
Unfolded Protein Response In Tumor Cells Modulate The Immunological Landscape Of The Tumour Microenvironment

- Introduce the concept of ER stress response/unfolded protein response (UPR) in cancer and effects on the tumor microenvironment
- Discuss the specific effects of cell-nonautonomous UPR on cancer cells
- Discuss the effect of cell-nonautonomous UPR on myeloid cells
- Discuss role of the UPR in PD-L1 expression

MAURIZIO ZANETTI, Director of Tumour Immuno-Oncology, University of California San Diego

Strategical Approaches In Developing Oncolytic Viruses For Immuno Therapy

- The utilization of native and engineered oncolytic viruses (OVs) as an approach in cancer immunotherapy exploits the key hallmarks of OVs to selectively replicate and kill tumor cells and to induce an immune response
- Merck is currently engaged in several on-going external collaborations to evaluate OVs including T-VEC, and DXN-2401 in combination with pembrolizumab (Keytruda)
- In addition, Merck is exploring an opportunity to use CAVATK (Coxsackievirus A21) as an Oncolytic Viruses along with Keytruda

VENKATESWARLU CHAMCHA, Senior Scientist, Merck

Targeting Soluble TNF To Reverse Trastuzumab Resistance

- MUC4 as a cause of trastuzumab resistance
- Role of soluble TNF in MUC4 expression in HER2+ breast cancer
- Using INB03 as part of combination therapy to reverse trastuzumab resistance

RAYMOND TESI, President & Chief Executive Officer, InMune Bio

Biomarkers For Pathway Inhibitor For Combination Therapy

- Mutations in DNA repair pathways are drivers in many cancers, including BRCA1, BRCA2 and genes in HRR pathway
- Mutations in HR pathway can sensitize tumors to PARP inhibitor
- High degrees of biallelic loss are observed for mutations in HRR pathways
- Mutations in HRR pathway are associated with higher degree of genome-wide LOH and tumor mutation burden (TMB)
- TMB has been associated with better response to immunotherapy
- Mutations in HRR pathway can be a biomarker for combination therapy of PARP inhibitor and immunotherapy

ZHONGWU LAI, Principal Scientist, Cancer Informatics, AstraZeneca

Engineered Toxin Bodies” — An Immunotoxin-Like Compound

- ETBs consist of a single-chain variable fragment genetically fused to Shiga-like toxin subunit A with high binding affinity for different oncologic targets—i.e. CD20, HER2
- The ETB targeting CD20, MT-3724, has completed dose escalation and has demonstrated monotherapy activity in subject with relapsed/refractory DLBCL
- MT-3724 is now in Phase 2 research as a monotherapy for patients with relapsed/refractory DLBCL and is being studied in combination with chemotherapy and immunomodulatory agents
- A second ETB, MT-5111, has entered First-in-Human clinical trials for patients with relapsed HER2-overexpressing malignancies, including breast, gastric, and other solid tumors

ROGER WALTZMAN, Chief Medical Officer, Molecular Templates
## Co-located Keynote Address: Precision Medicine To Identify An Objective Molecular Screening Tool For Early Indicators Of PTSD

- Post Traumatic Stress Disorder depends on accurate self-report
- Young Active Duty Service Members may not associate their symptoms as being PTSD or may fear 'stigma' or disruption of their career path and may not report accurately
- Applying global molecular and extensive clinical discovery, objective panels have been identified for construction of a screening tool for PTSD
- Biotypes/subgroups of PTSD were seen and have potential to aid in personalized therapy of PTSD

**Marti Jett**, Chief Scientist (ST) Systems Biology, US Army Center for Environmental Health Research

## Stream Keynote Address: Immunogenicity In The Context Of Cross-Reactivity And Immunomodulation

- Introduce the concept of TCR cross-reactivity
- Discuss ex vivo and in silico tools to assess immunogenicity
- Discuss clinical observations where immunogenicity to biologics is associated with cross-reactive TCRs and immunomodulation
- Discuss implications for neoepitope discovery

**Jad Maamary**, Associate Principal Scientist, Merck & Co Inc

## Delivering Innovative Solutions For Immuno-Oncology Drug Discovery

- Bespoke immunoassays for target validation, mode-of-action studies and combination immunotherapy design
- In vitro tumour killing, myeloid and regulatory cell suppression assays and immune response profiling
- Specialist multiplex histology for visualisation and co-localisation of targets

**Rhoanne McPherson**, Senior Scientist, Aquila BioMedical, A Concept Life Sciences Company
Supercharging The Tumor Microenvironment With The Engineered Cytokines NKTR-214 And NKTR-255

- Cytokines are powerful agents that can provide expansion and differentiation for effector cells. In their native state they are poor medicines
- Engineered cytokines can more effectively stimulate cytokine receptor pathways, while controlling adverse events
- The combination of NKTR-214 with Opdivo has demonstrated powerful anti-tumor effects and profoundly alters the tumor microenvironment, increasing effector T-cell counts, increasing PD-1 expression on tumor T-cells, and converting PD-L1 negative tumors to positive, while maintaining a more tolerable AE profile than traditional cytokine therapies
- NKTR-255 is an immune cytokine that can selectively grow NK cells and CD8 memory T cells in the patient's body. This allows for the potential to combine NKTR-255 with ADC: mabs and to induce long term survival of CAR-Ts

LOUI MADAKAMUTIL, Senior Vice President, Head of Preclinical Development, Nektar Therapeutics

Strategies For Improving The Analysis Of The Tumor Microenvironment

- The tumor microenvironment is a complex structure; understanding its composition is important for improving drug discovery and development
- Combining high dimensional flow cytometry with scRNAseq data allows more detailed analysis of the tumor microenvironment
- Choosing and optimizing the right mouse model that most closely reflects human cancer is of high importance to improve immune-oncological drug discovery

RUTH SEEILGE, Senior Scientist, Pfizer

Cirmtuzumab And Ibrutinib - Novel Synergistic Combination For CLL And Mantle Cell Lymphoma

- Cirmtuzumab targets ROR1, an oncofetal antigen expressed on both liquid and solid tumors
- Cirmtuzumab inhibits Wnt5a signalling and reverses stemness in CLL
- The ROR1 pathway is not inhibited by BTK inhibitors such as ibrutinib
- Cirmtuzumab and ibrutinib are synergistic for CLL and MCL, and a clinical trial of the combination is under way

GUNNAR KAUFMANN, Chief Scientific Officer, OncTernal Therapeutics

Dose Optimization Strategy

- The power of model-informed drug development in I-O
- Dose optimization for mono- and combo- therapy
- Global strategy

DI BEI, Senior Clinical Pharmacologist, Bristol-Myers Squibb

Dynamic Regulation Of OX40 Following Receptor Agonism: Implications For Antibody-Mediated Enhancement Of T-Cell Function

- BMS-986178-mediated enhancement of human CD4+ Teff responses and reversal of Treg suppression was dependent on antibody cross-linking Maximal Increases in activation, proliferation, and cytokine production mediated by BMS-986178 treatment occurred at ~20% receptor occupancy
- Low concentrations of BMS-986178 were sufficient to drive upregulation of OX40, both on the cell surface as well as the soluble receptor; but loss of surface OX40 was observed as receptor occupancy approached 100%

MARIE-CLAUDE GAUDREAU, Senior Research Investigator Immuno-Oncology Resistance Biology, Bristol-Myers Squibb

Clinical And Translational Results From The Phase I Combination Trial Of Durvalumab And Gefitinib In EGFR Mutant NSCLC (Non-Small Cell Lung Cancer)

- Durvalumab is an anti-PD-L1 antibody which has shown activity in lung cancer and currently approved for unrespectable, Stage III NSCLC that has not progressed following platinum-based chemotherapy and radiotherapy
- Gefitinib is a first-generation EGFR tyrosine kinase inhibitor which is approved for NSCLC with sensitizing EGFR mutations
- Final results from one of the earliest combination trials between an anti-PD-1/PD-L1 agent and an active tyrosine kinase inhibitor will be discussed

TAMMIE YEH, Associate Director, Oncology Translational Medicine, AstraZeneca

Next Generation iPSC Derived Off-The-Shelf Cellular Immunotherapies For Cancer

- Impaired starting material, high manufacturing costs and heterogenous genetic editing have limited broad adoption of current autologous CAR-T cell therapies
- Fate has developed a novel manufacturing process which uses clonal, master pluripotent stem cell lines as the starting material to generate uniform populations of highly efficacious engineered CAR-NK and CAR-T products
- In this presentation, I will discuss how we are leveraging this powerful platform to generate a pipeline of highly-edited iPSC derived off-the-shelf cell therapies for treating patients with cancer

DANIEL SHOEMAKER, Chief Scientific Officer, Fate Therapeutics

Next Generation Immune Checkpoints: Understanding Mechanism And Targeting In The Tumor Microenvironment

- The clinical success of CTLA-4 and PD-1/L1 checkpoint pathway blockade has ushered in an exciting era in immunotherapy
- Despite the great success, response rates remain insufficient and relapse/resistance occur
- A deep understanding of the suppressive tumor microenvironment as well as expression/mechanism of targets is critical for next-gen immunotherapy drug development

CATHERINE SABATOS-PETYON, Director, Novartis

IMU-301 Phase Ib Study Results Of HER2 B-cell Vaccine In HER2 Gastric Cancer

- Preclinical evidence for a HER2 B-cell vaccine in cancer therapeutics
- Clinical study design for a B-cell vaccine in HER2 positive Gastric Cancer
- Antibody and Clinical Response data from the phase Ib in HER2 positive Gastric Cancer
- Phase 2 study design in in HER2 positive Gastric Cancer

MARK T. MARINO, Chief Medical Officer, Imugene, Ltd

Panel Discussion: Technological Challenges In Clinical Studies

Panel Moderator: IAN WILSON, Chief Executive Officer, ImaginAB
Panelists include:
TAMMIE YEH, Associate Director, Oncology Translational Medicine, AstraZeneca
NAVEEN DAKAPPAGARI, Head, Protein Biomarker Solutions, Navigate BioPharma

Afternoon Coffee & Refreshments, Poster Presentation Sessions
15:30 - 16:00

**Multispecifíc And Multivalent Antibodies As OX40 Agonists**

- I will discuss strategies for the design and discovery of second generation IO agonists
- I will describe the in vitro characterization of INV531, our biparatopic OX40 agonist
- I will share in vivo efficacy and safety data for INV531

BRYAN GLASER, Vice President of Business Development, Invenra

---

16:00 - 16:30

**High-Throughput Interrogation Of Cancer Patient Repertoires For Discovery Of Anti-Tumor Antibodies**

- Patient antibody repertoires can be the source of potent anti-tumor antibodies that bind novel targets
- ATRC-101 (Ph1 ETA early 2020) is a recent example of a patient-derived antibody that exhibits potent anti-cancer activity in pre-clinical models
- Display-based interrogation of cancer patient antibody repertoires in a target-agnostic manner can be used as a high-throughput method for discovery of anti-tumor antibodies

SEAN CARROLL, Associate Director, Atreca

---

**PET Immunology Imaging Toolbox: The Evolution Of Imaging Agents Useful In Clinical Decision Making**

- Summary of imaging in Immuno-Oncology
- Key processes and measurements
- Value of Molecular imaging in Clinical trials
- Value of Molecular imaging in Clinical Practice

IAN WILSON, Chief Executive Officer, ImaginAB

---

Delegates are welcome to attend the co-located presentations
DoubleTree by Hilton San Diego - Mission Valley
7450 Hazard Center Drive, San Diego, California, 92108, USA
Tel: +1-619-297-5466

DoubleTree by Hilton San Diego - Mission Valley puts you in the center of San Diego. Mission Valley hotel is conveniently located next to the trolley stop, which offers easy transportation to a variety of the city's top attractions including Old Town, Little Italy, Petco Park, San Diego Convention Center, Gaslamp Quarter, and San Diego State University. It is easily accessible by rail, trolley, car, and air.

Detailed travel directions can be found at:  
www.oxfordglobal.co.uk/immunooncologyusa-congress/venue/

Also known as 'America’s Finest City', San Diego is home to Balboa Park, the largest urban cultural park in the U.S., that features 15 museums, numerous art galleries, beautiful gardens, the Tony Award-winning The Globe Theaters and the world-famous San Diego Zoo.
### Delegate Details

<table>
<thead>
<tr>
<th>Field</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td></td>
</tr>
<tr>
<td>Forename:</td>
<td></td>
</tr>
<tr>
<td>Surname:</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Company/Organisation:</td>
<td></td>
</tr>
<tr>
<td>Email:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>Postcode:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Direct Telephone:</td>
<td></td>
</tr>
<tr>
<td>Direct Fax:</td>
<td></td>
</tr>
<tr>
<td>Mobile:</td>
<td></td>
</tr>
<tr>
<td>Switchboard:</td>
<td></td>
</tr>
<tr>
<td>Signature:</td>
<td></td>
</tr>
<tr>
<td>Date:</td>
<td></td>
</tr>
</tbody>
</table>

### Registration Fees

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Academic Delegates</strong></td>
<td></td>
</tr>
<tr>
<td>Congress</td>
<td>$720</td>
</tr>
<tr>
<td>1-day pass</td>
<td>$445</td>
</tr>
<tr>
<td>Day 1</td>
<td></td>
</tr>
<tr>
<td>Day 2</td>
<td></td>
</tr>
<tr>
<td><strong>Vendor Delegates</strong></td>
<td></td>
</tr>
<tr>
<td>(CROs, Consultants, Technology and Service Providers)</td>
<td></td>
</tr>
<tr>
<td>Congress Only</td>
<td>$2,410</td>
</tr>
<tr>
<td><strong>Special Offer: 3 for 2</strong></td>
<td></td>
</tr>
<tr>
<td>Offer is only valid on the congress and for those registering at Industry or Academic rates</td>
<td></td>
</tr>
</tbody>
</table>

### Terms & Conditions of Booking

**Delegate Booking Fee**

The Delegate Booking Fee includes lunches and refreshments throughout the congress day, conference presentations and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser.

An admin surcharge of $70 will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online.

Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

**Acceptance of a Complimentary Pass**

If you are offered a free delegate pass and you are unable to attend the event, you may nominate a substitute of equal standing (in terms of business and financial responsibility). A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid a non-attendance charge of $320 being applied.

**Delegate Registration Form**

Each delegate must complete the online delegate registration form issued by the Organiser on receipt of the Delegate Booking Form. This information will only be used for the organisation of the conference, for material produced for delegates and sponsors and to facilitate the networking sessions.

**Cancellation and Curtailment**

If a Registered Delegate is unable to attend the event, he/she may nominate a substitute of equal standing within their company. A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid cancellation charges being applied. Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation:

<table>
<thead>
<tr>
<th>Duration</th>
<th>Cancellation Fee</th>
<th>Refund</th>
</tr>
</thead>
<tbody>
<tr>
<td>More than 6 months prior</td>
<td>30% cancellation fee / 65% refund</td>
<td></td>
</tr>
<tr>
<td>Between 6 and 3 months prior</td>
<td>70% cancellation fee / 25% refund</td>
<td></td>
</tr>
<tr>
<td>Less than 3 months prior to the event</td>
<td>Full cancellation fee / No refund</td>
<td></td>
</tr>
</tbody>
</table>

**Data Protection**

The data controller is the organiser (Oxford Global Marketing Ltd). The Organiser may disclose such personal information as name, company, job title, telephone and email address to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. Registration details will be retained and used in accordance with our privacy policy.

If you wish to opt out please email info@oxfordglobal.co.uk

**Miscellaneous**

The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegates’ Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking fee will be refunded.

For promotional purposes, there may be professional photography and video production taking place during the conference. Delegates who do not wish to be filmed or recorded should advise the Organiser by email to operations@oxfordglobal.co.uk prior to the Event.

These terms and conditions are binding upon the delegate submitting a registration form.

I agree to the above Terms and Conditions

### How to Pay

**CREDIT CARD**

An Oxford Global representative will contact you directly following return of contract / booking form to process card payment. If payment will be made by a colleague within your company, please complete the following;

Card Payment Contact Name: ____________________________

Phone Number: ____________________________

**INVOICE**

I cannot attend but would like to purchase access to the following:

- Access to the online conference presentations $690

Please choose one of the following payment options:

**Number of delegates:**

- Industry del(s) [ ]
- Academic del(s) [ ]
- Vendor del(s) [ ]

**Special Offer: 3 for 2**

Offer is only valid on the congress and for those registering at Industry or Academic rates

### Documentation

**PROMOTIONAL LITERATURE DISTRIBUTION**

Distribution of your company’s promotional literature to all conference attendees $1,380

**Mission Valley, San Diego, USA**

**WEBSITE:** www.oxfordglobal.co.uk/immunooncologyusa

**2nd Annual Advances in Immuno-Oncology USA Congress**

8 - 9 October 2019 | DoubleTree by Hilton Hotel San Diego – Mission Valley, San Diego, USA

**www.oxfordglobal.co.uk/immunooncologyusa-congress**

**HOW TO REGISTER:**

FAX your booking form to +44(0)1865 689120 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk
### FORTHCOMING EVENTS

#### Biologics Series
- **UK**
  - **13th Annual Proteins & Antibodies Congress**
    - 27 - 29 April 2020 | London, UK
  - **7th Annual Peptides Congress**
    - 27 - 29 April 2020 | London, UK
  - **2nd Annual Bispecifics in Discovery & Development Congress**
    - 27 - 29 April 2020 | London, UK

#### Biomarkers Series
- **UK**
  - **15th Annual Biomarkers Congress**
    - 18 - 20 February 2020 | Manchester, UK
  - **Genomic Markers Congress**
    - 18 - 20 February 2020 | Manchester, UK
  - **4th Annual Biomarkers & Precision Medicine USA Congress**
    - 08 - 09 October 2019 | San Diego, USA

#### Cell Series
- **UK**
  - **8th Annual Cell Culture & Bioprocessing Congress**
    - 29 - 30 October 2019 | London, UK
  - **6th Annual Stem Cell & Regenerative Medicine Congress**
    - 29 - 30 October 2019 | London, UK
  - **5th Annual Cell & Gene Therapy Congress**
    - 29 - 30 October 2019 | London, UK

#### Formulation & Delivery Series
- **UK**
  - **6th Annual Formulation & Drug Delivery Congress**
    - 22 - 23 April 2020 | London, UK
  - **5th Annual Inhalation & Respiratory Drug Delivery Congress**
    - 22 - 23 April 2020 | London, UK
  - **Biomanufacturing Congress**
    - 22 - 23 April 2020 | London, UK
  - **3rd Annual Formulation & Drug Delivery USA Congress**
    - 17 - 18 March 2020 | San Diego, USA
  - **3rd Annual Inhalation & Respiratory Drug Delivery USA Congress**
    - 17 - 18 March 2020 | San Diego, USA

#### Immuno Series
- **UK**
  - **5th Annual Advances in Immuno-Oncology Congress**
    - 21 - 22 May 2020 | London, UK
  - **Autoimmunity & Immunology Congress**
    - 21 - 22 May 2020 | London, UK
  - **2nd Annual Advances in Immuno-Oncology USA Congress**
    - 08 - 09 October 2019 | San Diego, USA

#### PharmaTec Series
- **UK**
  - **17th Annual Pharmaceutical IT & Data Congress**
    - 24 - 25 September 2020 | London, UK
  - **3rd Annual Artificial Intelligence in Drug Development Congress**
    - 24 - 25 September 2020 | London, UK
  - **Cyber Security & Data Protection in Pharma & Healthcare Congress**
    - 24 - 25 September 2020 | London, UK
  - **SmartLabs & Laboratory Informatics Congress**
    - 24 - 25 September 2020 | London, UK

#### R&D Series
- **EU**
  - **21st Annual Drug Discovery Summit**
    - 26 - 27 May 2020 | Berlin, Germany
  - **8th Annual Drug Design and Medicinal Chemistry Congress**
    - 26 - 27 May 2020 | Berlin, Germany
  - **2nd Annual Neuroscience Drug Discovery & Development Congress**
    - 26 - 27 May 2020 | Berlin, Germany

#### SynGen Series
- **UK**
  - **11th Annual Next Generation Sequencing & Clinical Diagnostics Congress**
    - 07 - 08 November 2019 | London, UK
  - **7th Annual Single Cell Analysis Congress**
    - 07 - 08 November 2019 | London, UK
  - **5th Annual Genome Editing Congress**
    - 07 - 08 November 2019 | London, UK
  - **2nd Annual Synthetic Biology Congress**
    - 07 - 08 November 2019 | London, UK
  - **Digital PCR Congress**
    - 07 - 08 November 2019 | London, UK

- **US**
  - **6th Annual Next Generation Sequencing USA Congress**
    - 07 - 08 April 2020 | Boston, USA
  - **6th Annual Single Cell Analysis USA Congress**
    - 07 - 08 April 2020 | Boston, USA
  - **4th Annual Genome Editing USA Congress**
    - 07 - 08 April 2020 | Boston, USA

### FOR MORE DETAILS, PLEASE VISIT WWW.oxfordglobal.co.uk

### COMPLIMENTARY RESOURCES

Visit [www.oxfordglobal.co.uk/immuno-oncology/resources](http://www.oxfordglobal.co.uk/immuno-oncology/resources) to gain access to our complimentary resources, including Webinar Recordings, Newsletters, Speaker Q&As, and more!